The story of Viagra, formerly marketed by copyright, presents a complex case study for backers considering the drug sector. Despite its initial success and impact of billions in earnings , the exclusivity expiration has opened the floodgates for alternative medications, significantly diminishing earnings potential . This shift raises doubts about t